Evidence mapPaperPMID 41209039Full record

ReviewBioinformatics advances2025

Computational strategies in tumor phylogenetics: evaluating multimodal integration and methodological trade-offs across study designs.

Chenghan Jiang, Zhe Wang, Ruoyu Wang, Shanshan Liang, Shuai Tao

Abstract readReview
In one paragraph

Review in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chenghan JiangThe Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China.ORCID https://orcid.org/0009-0008-7282-4830
Zhe WangThe Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China.
Ruoyu WangThe Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China.
Shanshan LiangThe Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China.ORCID https://orcid.org/0000-0002-1644-4496
Shuai TaoThe Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation: Tumor clonal evolution represents a dynamic ecosystem underpinned by genetic alterations and Darwinian selection, posing major challenges due to intratumoral heterogeneity and therapy resistance. Although computational methods have advanced significantly, current tools often focus on single data modalities, leaving important gaps in modeling spatial and non-genetic evolution. This review systematically surveys and assesses algorithmic progress across diverse study designs to identify key limitations and future directions. Results: We systematically evaluate over 20 computational tools across four study designs-cross-sectional, regional bulk, single-cell, and lineage tracing-and perform benchmarking of seven comparable tools. Multiomics integration approaches are shown to improve phylogenetic inference, yet challenges remain in mutation ordering and polyclonal detection. A novel spatiotemporal framework is proposed to link phylogenetic branch lengths with spatial transcriptomic gradients. Future efforts should prioritize multimodal data integration, scalable computational architectures, and clinically applicable models to translate evolutionary insights into precision oncology. Availability and implementation: This review provides a comprehensive survey and benchmarking of existing methods. The code and data used to generate the benchmarking figures and results are available at https://github.com/zlsys3/review_benchmark/tree/main/figure.

Identifiers

PMID41209039
PMCPMC12596152

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.